• Sean Maduck, President, Corcept Endocrinology at Corcept Therapeutics, reported option exercise and share sales dated July 1, 2026.
• Exercised stock options for 25,000 shares at USD 8.27.
• Sold 24,? shares totaling 25,000 shares across multiple trades at weighted average prices of about USD 87.33, USD 88.51, USD 89.31.
• Directly owned 9,755 shares following the transactions.
• Also reported indirect holdings of 109,717 shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-296296), on July 06, 2026, and is solely responsible for the information contained therein.